

Marnix Jansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7489830/publications.pdf>

Version: 2024-02-01

50
papers

3,473
citations

279798

23
h-index

243625

44
g-index

78
all docs

78
docs citations

78
times ranked

7012
citing authors

#	ARTICLE	IF	CITATIONS
1	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. <i>Nature Medicine</i> , 2013, 19, 614-618.	30.7	656
2	Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. <i>Nature Medicine</i> , 2016, 22, 105-113.	30.7	629
3	British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. <i>Gut</i> , 2019, 68, 1545-1575.	12.1	365
4	LKB1 and AMPK Family Signaling: The Intimate Link Between Cell Polarity and Energy Metabolism. <i>Physiological Reviews</i> , 2009, 89, 777-798.	28.8	188
5	Quantification of Crypt and Stem Cell Evolution in the Normal and Neoplastic Human Colon. <i>Cell Reports</i> , 2014, 8, 940-947.	6.4	179
6	Mst4 and Ezrin Induce Brush Borders Downstream of the Lkb1/Strad/Mo25 Polarization Complex. <i>Developmental Cell</i> , 2009, 16, 551-562.	7.0	137
7	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. <i>Clinical Cancer Research</i> , 2017, 23, 387-398.	7.0	128
8	The evolutionary landscape of colorectal tumorigenesis. <i>Nature Ecology and Evolution</i> , 2018, 2, 1661-1672.	7.8	99
9	Evolutionary history of human colitis-associated colorectal cancer. <i>Gut</i> , 2019, 68, 985-995.	12.1	97
10	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. <i>Cancer Cell</i> , 2019, 35, 441-456.e8.	16.8	82
11	Gastrointestinal Polyposis Syndromes. <i>Current Molecular Medicine</i> , 2007, 7, 29-46.	1.3	79
12	Plasma membrane recruitment of dephosphorylated β -catenin upon activation of the Wnt pathway. <i>Journal of Cell Science</i> , 2008, 121, 1793-1802.	2.0	75
13	Barrett oesophagus: lessons on its origins from the lesion itself. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 50-60.	17.8	72
14	Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i> , 2021, 53, 1174-1188.	1.8	71
15	Insights Into the Pathophysiology of Esophageal Adenocarcinoma. <i>Gastroenterology</i> , 2018, 154, 406-420.	1.3	58
16	Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. <i>Nature Communications</i> , 2017, 8, 1998.	12.8	57
17	Bcl-2 is a critical mediator of intestinal transformation. <i>Nature Communications</i> , 2016, 7, 10916.	12.8	55
18	Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. <i>Modern Pathology</i> , 2011, 24, 1229-1236.	5.5	41

#	ARTICLE	IF	CITATIONS
19	Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using digital pathology. <i>Gut</i> , 2020, 69, 811-822.	12.1	39
20	Recent advances in the detection and management of early gastric cancer and its precursors. <i>Frontline Gastroenterology</i> , 2021, 12, 322-331.	1.8	34
21	Tertiary lymphoid structures (TLS) identification and density assessment on H&E-stained digital slides of lung cancer. <i>PLoS ONE</i> , 2021, 16, e0256907.	2.5	34
22	Stromal Indian Hedgehog Signaling Is Required for Intestinal Adenoma Formation in Mice. <i>Gastroenterology</i> , 2015, 148, 170-180.e6.	1.3	33
23	Endoscopic tissue sampling – Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i> , 2021, 53, 1261-1273.	1.8	30
24	The Barrett's Gland in Phenotype Space. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 41-54.	4.5	27
25	Nasal polyposis in Peutz-Jeghers syndrome: a distinct histopathological and molecular genetic entity. <i>Journal of Clinical Pathology</i> , 2006, 60, 392-396.	2.0	20
26	Immunosuppressive niche engineering at the onset of human colorectal cancer. <i>Nature Communications</i> , 2022, 13, 1798.	12.8	19
27	Analysis of metastases rates during follow-up after endoscopic resection of early –high-risk– esophageal adenocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2022, 96, 237-247.e3.	1.0	18
28	Epithelial-Specific Loss of PTEN Results in Colorectal Juvenile Polyp Formation and Invasive Cancer. <i>American Journal of Pathology</i> , 2014, 184, 86-91.	3.8	17
29	Clonal Transitions and Phenotypic Evolution in Barrett's Esophagus. <i>Gastroenterology</i> , 2022, 162, 1197-1209.e13.	1.3	17
30	Evidence for hypoxia increasing the tempo of evolution in glioblastoma. <i>British Journal of Cancer</i> , 2020, 123, 1562-1569.	6.4	15
31	Aberrant intestinal stem cell lineage dynamics in Peutz-Jeghers syndrome and familial adenomatous polyposis consistent with protracted clonal evolution in the crypt. <i>Gut</i> , 2012, 61, 839-846.	12.1	14
32	What Makes an Expert Barrett's Histopathologist?. <i>Advances in Experimental Medicine and Biology</i> , 2016, 908, 137-159.	1.6	11
33	LKB1 as the ghostwriter of crypt history. <i>Familial Cancer</i> , 2011, 10, 437-446.	1.9	9
34	Comparison of two multiband mucosectomy devices for endoscopic resection of Barrett's esophagus-related neoplasia. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 3665-3672.	2.4	9
35	Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience. <i>World Journal of Gastroenterology</i> , 2018, 24, 4698-4707.	3.3	8
36	Establishing a clinical and molecular diagnosis for hereditary colorectal cancer syndromes: Present tense, future perfect?. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 1145-1155.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Quality indicators for Barrett's endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett's neoplasia. <i>Frontline Gastroenterology</i> , 2020, 11, 259-271.	1.8	6
38	VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. <i>JMIR Research Protocols</i> , 2019, 8, e13696.	1.0	4
39	Diversity Counts. <i>American Journal of Clinical Pathology</i> , 2011, 135, 878-888.	0.7	3
40	Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study. <i>BMJ Open</i> , 2019, 9, e032013.	1.9	3
41	Early detection and risk stratification of gastric cancer are likely to be refined with biopsies targeted through high-resolution-enhanced imaging. <i>Gut</i> , 2020, 69, 1710-1711.	12.1	3
42	The natural history of low-grade dysplasia in Barrett's esophagus and risk factors for progression. <i>JGH Open</i> , 2021, 5, 1019-1025.	1.6	3
43	Extension of early esophageal squamous cell neoplasia into ducts and submucosal glands and the role of endoscopic ablation therapy. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 832-842.e2.	1.0	3
44	Stain-free identification of tissue pathology using a generative adversarial network to infer nanomechanical signatures. <i>Nanoscale Advances</i> , 2021, 3, 6403-6414.	4.6	1
45	OTU-004...Shallow whole-genome sequencing predicts the future cancer risk of low-grade dysplastic lesions in ulcerative colitis. , 2018, , .		0
46	PTH-118...Histopathologist features predictive of diagnostic concordance amongst an international sample of pathologists diagnosing Barrett's dysplasia. , 2018, , .		0
47	PTU-051...Risk factors for progression of confirmed low grade dysplasia in a Barrett's tertiary referral centre. , 2019, , .		0
48	PTU-052...The natural history of low-grade dysplasia in patients with Barrett's oesophagus: a tertiary centre experience. , 2019, , .		0
49	Histopathology-led quality evaluation of endoluminal excision specimens "not a bad idea!. <i>Endoscopy</i> , 2021, , .	1.8	0
50	Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	0